KELNOR 1/35 Rx
Generic Name and Formulations:
Ethynodiol diacetate 1mg, ethinyl estradiol 35mcg, 21 tabs; inert (7 tabs).
Indications for KELNOR 1/35:
1 tab daily for 28 days; repeat.
Progestin + estrogen.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Smokers over 35 years of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval
- Flu Vaccine Recalled Due to Sub-Potency
- Heart Rate May Be an Indicator of Future Diabetes Risk
- Probiotic Mixture VSL#3 Shows Promise for Crohn's Recurrence
- Study: Beloranib Appears Safe, Efficacious for Weight Loss in Obesity
- Progress Toward Mind-Controlled Robotic Limbs
- Response to Resistance Exercise Depends on a Person's Genetic Risk for Obesity